BioCentury | Jun 17, 2019
Company News

Sanofi shies away from neuro gene therapy programs

...testing for sickle cell disease and β thalassemia. It inherited the program, which goes by ST-400...
...Monday. Neurocrine was up $2.10 to $86.02. Allison Johnson, Staff Writer Autologous CD34 + hematopoietic stem cells (BIVV003) ST-400 VY-AADC...
BioCentury | May 16, 2018
Translation in Brief

Sickle cell strides

...ST-400 last fall, and Sangamo plans to start a Phase I/II trial this half. BIVV003 (ST-400...
...cell disease. bluebird’s LentiGlobin BB305 is in a Phase I for the indication. Allison Johnson, Staff Writer ST-400 Bioverativ...
BioCentury | Apr 27, 2018
Financial News

Sangamo raises $200M in follow-on

...NYSE:PFE). This half, Sangamo intends to begin enrolling patients in a Phase I/II trial of ST-400...
...June 2017, Sangamo raised $83.4 million in a follow-on. Sangamo Therapeutics Inc. (NASDAQ:SGMO), Richmond, Calif. Paul Bonanos SB-318 SB-913 ST-400 ZFN...
BioCentury | Apr 26, 2018
Financial News

Sangamo raises $200M in follow-on

...This half, Sangamo intends to begin enrolling patients in a Phase I/II trial of ST-400...
BioCentury | Oct 26, 2017
Tools & Techniques

Ripe for enhancement

...two other companies see opportunity in enhancers. Sangamo Therapeutics Inc. has submitted an IND for ST-400...
...preclinical development for sickle cell disease, would be the first to directly target an enhancer. ST-400...
...intron 2 of BCL11A, which gave them the best results for erythroid-specific expression, he said. ST-400...
Items per page:
1 - 5 of 5